Skin-soothing composition

Abstract

To provide a skin-soothing composition that includes epicatechin or a soybean extract including epicatechin, as an active ingredient.SOLUTION: A skin-soothing composition of the present invention comprises epicatechin or a soybean extract including epicatechin as an active ingredient, and the soybean extract is preferably an extract of a new variety of soybean having the deposit number of KCTC14220BP. The soybean extract more preferably includes 2 wt.% to 7 wt.% of epicatechin based on a total weight of an 80 wt.% ethanol aqueous solution extract of the new variety of soybean.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] This description relates to skin soothing compositions and cosmetic compositions containing same. [Background technology]

[0002] Sensitive skin reacts more easily to external stimuli than normal skin, causing irritation, erythema, and itching. Sensitive skin does not have significant differences in moisture content, pH, or melanin compared to normal skin, but it is reported to have a higher rate of water loss (TEWL) and secretion of cytokines.

[0003] As mentioned above, various symptoms occurring in sensitive skin can be alleviated by supplementing lipids in the stratum corneum of the skin mainly with ceramides to prevent evaporation of moisture.

[0004] On the other hand, examples of sensitive skin include atopic dermatitis and eczema, whose typical symptoms include redness and itching. Itching can occur due to a loss of moisturizing factors such as filaggrin and ceramide caused by damage to the skin barrier, or due to activation of nerve fibers triggered by histamine release caused by degranulation of mast cells due to various external stimuli. Therefore, skin itching can be alleviated by replenishing moisturizing factors to the skin to strengthen the skin barrier, or by inhibiting mast cell degranulation to suppress histamine release and nerve fiber activation. Conventionally, itching has been alleviated by replenishing moisturizing factors to the skin and strengthening the skin barrier. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Laid-Open No. 2014-18103 Summary of the Invention [Problem to be solved by the invention]

[0006] One embodiment provides a composition that can inhibit mast cell degranulation and increase claudin-1 protein expression.

[0007] Another embodiment provides a cosmetic composition that can relieve skin itching, strengthen the skin barrier, and soothe the skin. [Means for solving the problem]

[0008] According to one embodiment, there is provided a skin soothing composition containing epicatechin or a soybean extract containing epicatechin as an active ingredient.

[0009] The soybean extract may be an extract of a new variety of soybean with accession number KCTC14220BP.

[0010] The soybean extract may contain 2% to 7% by weight of epicatechin based on the total weight of the 80% by weight aqueous ethanol extract of the new variety soybean.

[0011] The epicatechin or soybean extract containing the same may be contained in an amount of 1 ppm to 5,000 ppm based on the total weight of the composition.

[0012] The skin soothing may be due to the relief or suppression of itching.

[0013] The skin soothing may be due to an improved skin barrier.

[0014] The skin soothing may be due to the maintenance of skin moisture.

[0015] The skin soothing may be due to flushing suppression.

[0016] The skin soothing effect may be due to improved skin cohesion.

[0017] The skin soothing may be due to the improvement of skin allergies.

[0018] According to another embodiment, a cosmetic composition is provided that includes the skin composition.

[0019] The cosmetic composition may contain 0.1% to 10% by weight of the skin soothing composition, based on the total weight of the cosmetic composition.

[0020] The cosmetic composition may be a cosmetic composition for relieving itching.

[0021] The relief of itching can be characterized by suppressing degranulation of mast cells to relieve itching.

[0022] According to another embodiment, there is provided a method for treating skin itching, comprising applying the cosmetic composition to the skin of an individual in whom itching has been induced.

[0023] The composition according to one embodiment can inhibit mast cell degranulation and increase claudin-1 protein expression, and therefore, a cosmetic composition according to another embodiment containing the composition can relieve skin itching and strengthen the skin barrier. [Brief explanation of the drawings]

[0024] [Figure 1] 1 is a graph showing the results of evaluating the inhibition of induction of mast cell degranulation. [Figure 2] 10 is a photograph of the artificial skin for the skin bonding strength evaluation results. [Figure 3] 10 is a photograph of artificial skin for the moisturizing factor evaluation results. [Figure 4] 1 is a graph of the results for skin flushing assessment. DETAILED DESCRIPTION OF THE INVENTION

[0025] DETAILED DESCRIPTION OF THE INVENTION The present invention will now be described in detail with reference to exemplary embodiments thereof so that those skilled in the art can easily understand and practice the invention. However, the present invention may be embodied in many different forms and is not limited to the exemplary embodiments set forth herein.

[0026] As used herein, the term "active ingredient" refers to an ingredient that can exhibit a desired activity alone or can exhibit an activity together with a carrier that is inactive by itself.

[0027] One embodiment provides a skin soothing composition that includes epicatechin or a soy extract containing epicatechin as an active ingredient.

[0028] Mast cells are immune cells that are the primary cause of allergies. Their surface contains surface factors that can bind to IgE antibodies. When IgE antibodies bind to the surface of mast cells, the mast cells become activated. The activated mast cells degranulate neurotransmitters such as histamine, and newly synthesize and secrete lipid mediators such as cytokines, prostaglandins, and leukotrienes, which can cause itching. Furthermore, inflammatory factors secreted during mast cell degranulation weaken the intercellular bonds in the granular layer, weakening skin's bond strength, making the skin more susceptible to external stimuli.

[0029] The inventors of the present application have confirmed that a composition containing epicatechin or a soybean extract containing epicatechin according to one embodiment can soothe the skin by inhibiting the degranulation of mast cells, thereby suppressing histamine release and the activation of nerve fibers, thereby relieving skin itching, and that the composition exhibits effects similar to those of ketotifen, a conventional anti-itch agent. Furthermore, the inventors have confirmed that the composition inhibits the degranulation of mast cells, thereby improving the skin barrier, maintaining skin moisture, suppressing skin flushing, improving skin cohesion, and alleviating skin allergies, and therefore the composition can ultimately soothe the skin.

[0030] Here, the itch-relieving effect does not refer to the alleviation of itch through anti-inflammatory activity, but rather to the alleviation of itch through the inhibition of mast cell degranulation. Generally, anti-inflammatory refers to an activity for preventing or ameliorating inflammation, such as preventing inflammation from occurring in tissues of an individual, including skin, or alleviating inflammation. Inflammation includes inflammation occurring in tissues, including skin, due to external stress, such as ultraviolet rays or oxidants, and the tissue may be skin tissue or tissue other than skin, such as lung tissue. Inflammation can itself become a disease, such as atopic dermatitis or chronic obstructive pulmonary disease (COPD). However, the composition according to one embodiment is not related to the anti-inflammatory activity of preventing or alleviating inflammation. That is, rather than managing inflammation caused by external stress, the composition according to one embodiment is completely different from conventional anti-itch compositions based on an anti-inflammatory response in that it suppresses mast cell degranulation to relieve or soothe itch in patients with dry skin and a congenital weak skin barrier, where redness, pulling, itching, etc. frequently occur unrelated to external stress. Moreover, the two compositions are completely different in structure and mechanism in that conventional anti-itch compositions based on an anti-inflammatory response (or anti-aging or anti-oxidation response) are unrelated to the suppression of mast cell degranulation. (Most existing anti-itch compositions have maximized anti-inflammatory effects by suppressing genes such as PGE2, PLA2, COX-2, IL-2, IL-3, IL-4, IL-13, and TSLP, thereby relieving itching.) Additionally, ketotifen, a drug used to treat itching, selectively inhibits histamine release by inhibiting degranulation, thereby reducing itching through the suppression of histamine caused by external or internal stimuli.

[0031] In addition, it was confirmed that the composition containing epicatechin or a soybean extract containing epicatechin increases the expression of claudin-1 protein, which is involved in tight junctions, and strengthens skin with weakened cell binding, thereby relieving skin itching and soothing the skin.

[0032] The epicatechin contained in the composition may be represented by, but is not limited to, the following Chemical Formula 1:

[0033] [ka]

[0034] The soybean extract can be obtained by extracting a new variety of soybean with the accession number KCTC14220BP, and the new variety of soybean can be obtained by crossbreeding IT109098 (flat soybean) as the female plant with the semi-wild species K7-2 as the male plant.

[0035] The new soybean extract may contain epicatechin at a concentration of 2% by weight or more, 2.1% by weight or more, 2.2% by weight or more, 2.3% by weight or more, 2.4% by weight or more, 2.5% by weight or more, 2.6% by weight or more, 2.7% by weight or more, 2.8% by weight or more, 2.9% by weight or more, 3% by weight or more, 3.1% by weight or more, 3.2% by weight or more, 3.3% by weight or more, 3.4% by weight or more, 3.5% by weight or more, 3.6% by weight or more, 3.7% by weight or more, 3.8% by weight or more, 3.9% by weight or more, 4% by weight or more, 4.1% by weight or more, or 4.2% by weight or more, based on the total weight of an extract obtained by extracting new soybeans with an 80% aqueous ethanol solution. Alternatively, the epicatechin content may be 7% by weight or less, 6.8% by weight or less, 6.6% by weight or less, 6.4% by weight or less, 6.2% by weight or less, 6% by weight or less, 5.8% by weight or less, 5.6% by weight or less, or 5.4% by weight or less. By containing epicatechin in the soybean extract within this range, the itching-relieving effect of a composition containing the same can be maximized.

[0036] The skin soothing composition may contain epicatechin or a soybean extract containing epicatechin in an amount of 1 ppm to 1,000 ppm, for example, 1 ppm to 900 ppm, for example, 1 ppm to 800 ppm, for example, 1 ppm to 700 ppm, for example, 1 ppm to 600 ppm, for example, 1 ppm to 500 ppm, for example, 2 ppm to 1,000 ppm, for example, 3 ppm to 1,000 ppm, for example, 4 ppm to 1,000 ppm, for example, 5 ppm to 1,000 ppm, for example, 10 ppm to 1,000 ppm, for example, 10 ppm to 500 ppm, but is not limited thereto. By including epicatechin or a soybean extract containing epicatechin in the composition within the above range, the itching relief effect of the composition can be maximized.

[0037] The skin soothing composition can soothe the skin in various ways, such as by alleviating or suppressing itchy skin symptoms, by maintaining skin moisture, by suppressing skin flushing, by improving the cohesion of skin cells or the skin barrier, and by improving the occurrence of skin allergies.

[0038] Another embodiment provides a cosmetic composition comprising the composition for inhibiting mast cell degranulation.

[0039] The cosmetic composition may contain, based on the total weight, the composition for inhibiting mast cell degranulation in an amount of, for example, 0.1 wt % to 10 wt %, for example, 0.1 wt % to 10 wt %, for example, 0.1 wt % to 9 wt %, for example, 0.1 wt % to 8 wt %, for example, 0.1 wt % to 7 wt %, for example, 0.1 wt % to 6 wt %, for example, 0.1 wt % to 5 wt %, for example, 0.2 wt % to 10 wt %, for example, 0.3 wt % to 10 wt %, for example, 0.4 wt % to 10 wt %, for example, 0.5 wt % to 10 wt %, for example, 0.6 wt % to 10 wt %, for example, 0.7 wt % to 10 wt %, for example, 0.8 wt % to 10 wt %, for example, 0.9 wt % to 10 wt %, for example, 1.0 wt % to 10 wt %, but is not limited thereto. By containing the composition for inhibiting mast cell degranulation in the cosmetic composition within the above content range, the cosmetic composition can be used without causing other side effects on the skin and can maximize its itching relief effect.

[0040] The cosmetic composition can relieve skin itching. Skin itching can be caused by a loss of skin moisturizing factors due to a dry external environment, or by mast cell degranulation. When applied to the skin, the cosmetic composition inhibits mast cell degranulation, suppresses histamine release, and inhibits nerve fiber activation, thereby relieving skin itching. It also inhibits skin flushing and the occurrence of skin allergies, resulting in skin soothing. The cosmetic composition also strengthens the tight junction of cells in the granular layer of the epidermis, i.e., strengthens cell binding, improving the skin barrier and relieving skin itching. Furthermore, by strengthening skin cell binding, it inhibits the loss of skin moisturizing factors and maintains skin moisture, thereby relieving and soothing skin itching. Since the cosmetic composition is essentially applied to the skin, it can be prepared using any formulation commonly prepared with reference to cosmetic compositions in the art. For example, it may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, emulsion obtained by dispersing an oil phase in an aqueous phase, emulsion obtained by dispersing an aqueous phase in an oil phase, microneedle, foam, aerosol, wax foundation, spray, etc., but is not limited to these.

[0041] The cosmetic composition may have a formulation such as, for example, a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, an eye cream, an eye essence, an essence, a cleansing cream, a cleansing lotion, a cleansing foam, a cleansing water, a pack, a powder, a body lotion, a body cream, a body essence, a body wash, a hair dye, a shampoo, a conditioner, a hair styling product, a wool treatment, an ointment, a gel, a cream, a patch, a spray, a powder, and a skin adhesive type, but is not limited thereto.

[0042] In the preparation, ingredients other than the essential ingredients can be easily selected and blended by those skilled in the art depending on the type or purpose of use of other topical preparations.

[0043] When the cosmetic composition is formulated as a paste, cream, or gel, the carrier component may include animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc.

[0044] When the cosmetic composition is formulated as a powder or spray, carrier components may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc., and particularly when the cosmetic composition is formulated as a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, dimethyl ether, etc.

[0045] When the cosmetic composition is formulated as a solution or emulsion, the carrier components may include solvents, solubilizers, emulsifiers, etc., and specifically, may include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, fatty acid esters of sorbitan, etc.

[0046] When the cosmetic composition is formulated as a suspension, the carrier component may include a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester; or microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant.

[0047] When the formulation of the cosmetic composition is a surfactant-containing cleanser, the carrier component may include fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, ranoluli derivatives, ethoxylated glycerol fatty acid esters, and the like.

[0048] Meanwhile, another embodiment provides a method for treating skin itching, comprising applying the cosmetic composition to the skin of an individual in whom itching has been induced.

[0049] The step of applying the cosmetic composition to the skin of an individual suffering from itching may be carried out in any form that can achieve the desired effect, such as by application, injection, etc. Furthermore, the method for treating skin itching refers to a method for reducing symptoms of skin itching, such as by alleviating, suppressing, or reducing skin itching.

[0050] The above-mentioned embodiments of the present invention will be described in more detail below through examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0051] Soybean extract manufacturing Manufacturing example A new variety of soybean (accession number KCTC14220BP) was ground using a grinder (Tube Mill 100 Control, IKA) to produce powder. 100 g of the resulting soybean powder was added to 1 L of 80% aqueous ethanol and extracted at room temperature (25°C) for 24 hours. The extract was then filtered using filter paper. The filtered extract was then dried using a vacuum concentrator to obtain 15.7 g of extract.

[0052] Preparation of the composition Example 1 A stock was prepared by adding 1 g of epicatechin (EC, CAS No. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting it to 1 ppm using a medium to prepare a skin soothing composition.

[0053] Example 2 A stock was prepared by adding 1 g of epicatechin (EC, CAS No. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting the stock to 10 ppm using a medium to prepare a skin soothing composition.

[0054] Example 3 A stock was prepared by adding 1 g of epicatechin (EC, CAS No. 490-46-0) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting it to 50 ppm using a medium to prepare a skin soothing composition.

[0055] Example 4 1 g of the soybean extract obtained in the above Preparation Example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock, which was then diluted to 1 ppm using a medium to prepare a skin soothing composition.

[0056] Example 5 1 g of the soybean extract obtained in the above Preparation Example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock, which was then diluted to 10 ppm using a medium to prepare a skin soothing composition.

[0057] Example 6 1 g of the soybean extract obtained in the above Preparation Example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock, which was then diluted to 50 ppm using a medium to prepare a skin soothing composition.

[0058] Example 7 1 g of the soybean extract obtained in the above Preparation Example was added to 100 g of purified water or dimethyl sulfoxide (DMSO) to prepare a stock, which was then diluted to 100 ppm using a medium to prepare a skin soothing composition.

[0059] Comparative Example 1 Purified water or dimethyl sulfoxide (DMSO) was used.

[0060] Comparative Example 2 A stock was prepared by adding 1 g of palmitoylethanolamide (PEA) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluted to 1 ppm with a medium to prepare a composition.

[0061] Comparative Example 3 A stock was prepared by adding 1 g of palmitoylethanolamide (PEA) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluted to 10 ppm with a medium to prepare a composition.

[0062] Comparative Example 4 A stock was prepared by adding 1 g of palmitoylethanolamide (PEA) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting it to 50 ppm with medium to prepare a composition. At 50 ppm, the PEA was suspended and was not used in the experiment.

[0063] Comparative Example 5 A stock was prepared by adding 1 g of (-)-epigallocatechin gallate (EGCG) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting the stock to 1 ppm using a medium to prepare a composition.

[0064] Comparative Example 6 A stock was prepared by adding 1 g of (-)-epigallocatechin gallate (EGCG) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting the stock to 10 ppm using a medium to prepare a composition.

[0065] Comparative Example 7 A stock was prepared by adding 1 g of (-)-epigallocatechin gallate (EGCG) to 100 g of purified water or dimethyl sulfoxide (DMSO), and then diluting it to 50 ppm with medium to prepare a composition. EGCG at 50 ppm was not used in the experiment due to its cytotoxicity.

[0066] The components and concentrations in the compositions of Examples 1 to 6 and Comparative Examples 1 to 7 are summarized in Table 1 below.

[0067] [Table 1]

[0068] Evaluation 1: Evaluation of degranulation induction inhibition 1) Cultivation of RBL-2H3 cell line The RBL-2H3 cell line (basophil leukemia cell line) was obtained from the Korean Cell Line Bank (22256) and cultured in a CO2 incubator at 37°C under 5% CO2 conditions. The culture medium was DMEM media (with 10% FBS, 1% antibiotics).

[0069] 2) Treatment of RBL-2H3 cells with substances The RBL-2H3 cells were dispensed into a 96-well cell culture dish at 4 x 104 cells / well and cultured in an incubator at 37°C and 5% CO2 until they reached approximately 80% confluency. After that, the cells were treated with the allergen DNP-IgE (200 ng / ml) for 1 day, and then the secondary mast cells were activated with DNP-BSA (1 μg / ml) and treated with the compositions of Examples 1 to 6 and Comparative Examples 1, 2, 3, 5, and 6.

[0070] 3) Measurement of mast cell degranulation (β-hexosaminidase assay) After culturing the cells treated with the substances in step 2 in an incubator for 1 hour, 50 μl of the sup from each well was transferred to a new 96-well plate, and 50 μl of substrate solution was added. The cells were then incubated in an incubator for 1 hour. 100 μl of stop solution was added, and after confirming a yellow color, the absorbance was measured at 405 nm. Triton-X100 was used as a positive substance. The results are shown in Figure 1.

[0071] 1, it was confirmed that mast cell degranulation was significantly inhibited when treated with the compositions of Examples 1 to 6 compared to the compositions of Comparative Examples 1, 2, 3, 5, and 6 treated with DNP-lgE and DNP-BSA. That is, it can be seen that the induction of mast cell degranulation induced by allergens is inhibited when treated with a composition containing epicatechin or a soybean extract containing epicatechin. Therefore, it can be seen that cosmetic compositions containing the compositions can exert an effect of suppressing skin allergies caused by mast cell degranulation while alleviating or suppressing skin itching.

[0072] Evaluation 2: Evaluation of skin binding strength and moisturizing factor After applying the inflammatory cocktail (IFN-r (20 ng / ml) + TNF-α (20 ng / ml)) and the compositions of Comparative Examples 1, 4, 7, Examples 3, and 6 to artificial skin, the expression levels of the weakened skin binding factor claudin-1 protein and moisturizing factor filaggrin protein were compared, and the results are shown in Figures 2 and 3, respectively.

[0073] Referring to Figure 2, when artificial skin was treated with only the inflammatory cocktail, claudin-1 protein expression was reduced, weakening cell-cell binding and blurring the boundaries between cell layers. It was confirmed that the artificial skin treated with the compositions of Comparative Examples 1, 4, and 7 did not recover from the reduction in claudin-1 protein expression and still had unclear boundaries between cell layers. On the other hand, it was confirmed that the artificial skin treated with the compositions of Examples 3 and 6 recovered from the reduction in claudin-1 protein expression and had relatively clear boundaries between cell layers. This indicates that the compositions according to the examples containing epicatechin or a soybean extract containing epicatechin are effective in increasing the amount of claudin-1 protein expression.

[0074] Referring to Figure 3, when artificial skin was treated with only the inflammatory cocktail, the expression of the moisturizing factor filaggrin protein was reduced, and the boundaries between cell layers became blurred. It was confirmed that the artificial skin treated with the compositions of Comparative Examples 1, 4, and 7 did not recover from the reduction in filaggrin protein expression, and the boundaries between cell layers remained unclear. On the other hand, it was confirmed that the artificial skin treated with the compositions of Examples 3 and 6 recovered from the reduction in filaggrin protein expression, and the boundaries between cell layers became relatively clear. In other words, it can be seen that the compositions according to the examples containing epicatechin or a soybean extract containing epicatechin are effective in increasing the expression level of filaggrin protein.

[0075] On the other hand, referring to Figures 2 and 3, it can be seen that the decrease in claudin-1 and filaggrin protein expression was not restored even when the composition of Comparative Example 4 containing palmitoylethanolamide (PEA), which is known to have no inhibitory effect on mast cell degranulation and to have an inhibitory effect on skin inflammation, was treated.

[0076] From the results of evaluations 2 and 3, it can be seen that the composition containing epicatechin or a soy extract containing epicatechin improves the tight junctions between cells in the granular layer of the skin, thereby reducing water loss from the skin, improving skin moisturizing power, and strengthening the skin barrier.

[0077] Evaluation 3: Skin flushing evaluation Artificial skin was treated with inflammatory factors (TNF-α + IFN-r (20 ng / ml)), and the compositions of Examples 2, 3, 5, 6, and 7 and Comparative Examples 3, 4, 6, and 7 were applied, after which the amount of PGE2 (Prostaglandin E2) was measured. PGE2 is a factor that induces vasodilation and causes skin flushing, and it can be interpreted that the lower the amount of PGE2, the less vasodilation is induced and the more suppressed skin flushing is. The results of the skin flushing evaluation are shown in Figure 4.

[0078] 4, it can be seen that the amount of PGE2 is suppressed when the compositions according to Examples 3, 6, and 7 are applied. Therefore, it can be seen that the compositions containing epicatechin or soybean extracts containing epicatechin can suppress the occurrence of skin flushing.

[0079] Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also fall within the scope of the present invention. [Accession number]

[0080] Korea Institute of Biotechnology and Life Sciences, KCTC14220BP

Claims

1. A skin soothing composition comprising epicatechin or a soybean extract containing epicatechin as an active ingredient.

2. 2. The skin soothing composition according to claim 1, wherein the soybean extract is an extract of a new variety of soybean with accession number KCTC14220BP.

3. 3. The skin soothing composition of claim 2, wherein the soybean extract contains 2% to 7% by weight of epicatechin based on the total weight of an 80% by weight aqueous ethanol extract of the new variety soybean.

4. The skin soothing composition according to claim 1, wherein the epicatechin or soybean extract containing the epicatechin is contained in an amount of 1 ppm to 5,000 ppm based on the total weight of the composition.

5. The skin soothing composition of claim 1 , wherein the skin soothing is achieved by alleviating or suppressing itching.

6. The skin soothing composition according to claim 1, wherein the skin soothing is achieved by improving the skin barrier.

7. The skin soothing composition of claim 1 , wherein the skin soothing effect is achieved by maintaining skin moisture.

8. 10. The skin soothing composition of claim 1, wherein said skin soothing is achieved by suppressing flushing.

9. The skin soothing composition according to claim 1 , wherein the skin soothing effect is achieved by improving skin cohesion.

10. The skin soothing composition according to claim 1, wherein the skin soothing effect is achieved by improving skin allergies.

11. A cosmetic composition comprising the skin soothing composition according to any one of claims 1 to 10.

12. The cosmetic composition according to claim 11, wherein the cosmetic composition comprises 0.1% to 10% by weight of the skin soothing composition, based on the total weight of the cosmetic composition.

13. The cosmetic composition according to claim 11, wherein the cosmetic composition is for relieving itching.

14. The cosmetic composition according to claim 13, wherein the itching is alleviated by inhibiting degranulation of mast cells.

Images